SCHEMBL24633725

SCHEMBL24633725

C=CCOCC(C)(N)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.37
ALDH1A1 P00352 2/20 0.36
ARG1 P05089 1/20 0.34
ARG2 P78540 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
BLM P54132 2/20 0.33
MAPT P10636 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
EGFR P00533 1/20 0.31
CYP1A2 P05177 1/20 0.31
FYN P06241 1/20 0.31
POLB P06746 1/20 0.31
CYP3A4 P08684 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
APEX1 P27695 1/20 0.31
ADRA1A P35348 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25315695 1.00 GGT1 (0.37) GGT1ALDH1A1ARG1ARG2TDP1
SCHEMBL25315606 1.00 GGT1 (0.37) GGT1ALDH1A1ARG1ARG2TDP1
SCHEMBL12581238 0.82 ACLY (0.35) ALDH1A1TDP1MEN1POLBCYP3A4
SCHEMBL21340475 0.80 TSHR (0.38) TDP1MEN1POLBKMT2AL3MBTL1
SCHEMBL25315310 0.78 ARG1 (0.47) GGT1ARG1ARG2TDP1MEN1
SCHEMBL25314853 0.78 ARG1 (0.47) GGT1ARG1ARG2TDP1MEN1
SCHEMBL25314855 0.78 ARG1 (0.47) GGT1ARG1ARG2TDP1MEN1
Pivalate SCHEMBL9055894 0.77 TDP1 (0.35) ALDH1A1TDP1MAPTMEN1POLB
SCHEMBL27807043 0.76 L3MBTL1 (0.34) KDM4EL3MBTL1
SCHEMBL27807040 0.76 L3MBTL1 (0.34) KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023214576-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS 中外製薬株式会社 2023-11-09 WO disclosed
US-20230235301-A1 Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2023-07-27 US disclosed
WO-2022234853-A1 CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS 中外製薬株式会社 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230235301-A1 Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis STING1, TK1, PCNA GGT1 272/4885ALDH1A1 1454/4885ARG1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.